<!DOCTYPE html>
<html>

<head>
  <meta charset="utf-8">
  <!-- Meta tags for social media banners, these should be filled in appropriatly as they are your "business card" -->
  <!-- Replace the content tag with appropriate information -->
  <meta name="description" content="A dual-receptor model of serotonergic psychedelics">
  <meta property="og:title" content="A dual-receptor model of serotonergic psychedelics" />
  <meta property="og:description" content="A dual-receptor model of serotonergic psychedelics" />
  <meta property="og:url" content="https://awjuliani.github.io/dual-receptor-site/" />
  <!-- Path to banner image, should be in the path listed below. Optimal dimenssions are 1200X630-->
  <meta property="og:image" content="static/image/fig1.png" />
  <meta property="og:image:width" content="1686" />
  <meta property="og:image:height" content="980" />


  <meta name="twitter:title" content="A dual-receptor model of serotonergic psychedelics">
  <meta name="twitter:description" content="A dual-receptor model of serotonergic psychedelics">
  <!-- Path to banner image, should be in the path listed below. Optimal dimenssions are 1200X600-->
  <meta name="twitter:image" content="static/images/fig1.png">
  <meta name="twitter:card" content="summary_large_image">
  <!-- Keywords for your paper to be indexed by-->
  <meta name="keywords" content="predictive processing, psychedelics, psychotherapy, neuroscience, serotonin, energy-based models">
  <meta name="viewport" content="width=device-width, initial-scale=1">


  <title>A dual-receptor model of serotonergic psychedelics
  </title>
  <link rel="icon"
    href="data:image/svg+xml,<svg xmlns=%22http://www.w3.org/2000/svg%22 viewBox=%220 0 100 100%22><text y=%22.9em%22 font-size=%2290%22>ðŸ§ </text></svg>">
  <link href="https://fonts.googleapis.com/css?family=Google+Sans|Noto+Sans|Castoro" rel="stylesheet">

  <link rel="stylesheet" href="static/css/bulma.min.css">
  <link rel="stylesheet" href="static/css/bulma-carousel.min.css">
  <link rel="stylesheet" href="static/css/bulma-slider.min.css">
  <link rel="stylesheet" href="static/css/fontawesome.all.min.css">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jpswalsh/academicons@1/css/academicons.min.css">
  <link rel="stylesheet" href="static/css/index.css">

  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
  <script src="https://documentcloud.adobe.com/view-sdk/main.js"></script>
  <script defer src="static/js/fontawesome.all.min.js"></script>
  <script src="static/js/bulma-carousel.min.js"></script>
  <script src="static/js/bulma-slider.min.js"></script>
  <script src="static/js/index.js"></script>
</head>

<body>


  <section class="hero">
    <div class="hero-body">
      <div class="container is-max-desktop">
        <div class="columns is-centered">
          <div class="column has-text-centered">
            <h1 class="title is-1 publication-title">A dual-receptor model of serotonergic psychedelics: therapeutic
              insights from simulated cortical dynamics</h1>
            <div class="is-size-5 publication-authors">
              <!-- Paper authors -->
              <span class="author-block">
                <a href="https://awjuliani.github.io/" target="_blank">Arthur Juliani<sup>a</sup></a>,
              </span>
              <span class="author-block">
                <a href="https://veronicachelu.github.io/" target="_blank">Veronica Chelu<sup>b,c</sup></a>,
              </span>
              <span class="author-block">
                <a href="https://scholar.google.com/citations?user=0NHagNQAAAAJ&hl=en" target="_blank">Laura
                  Graesser<sup>d</sup></a>,
              </span>
              <span class="author-block">
                <a href="https://hopkinspsychedelic.org/safron" target="_blank">Adam Safron<sup>e</sup></a>
              </span>
            </div>

            <div class="is-size-5 publication-authors">
              <span class="author-block"><sup>a</sup>Microsoft Research, <sup>b</sup>McGill University, <sup>c</sup>Mila Quebec AI Institute,
                <sup>d</sup>Unaffiliated, <sup>e</sup>Johns Hopkins University</span>
            </div>

            <div class="column has-text-centered">
              <div class="publication-links">
                <!-- Arxiv PDF link -->
                <span class="link-block">
                  <a href="https://www.biorxiv.org/content/10.1101/2024.04.12.589282v2.full.pdf" target="_blank"
                    class="external-link button is-normal is-rounded is-dark">
                    <span class="icon">
                      <i class="fas fa-file-pdf"></i>
                    </span>
                    <span>Paper</span>
                  </a>
                </span>

                <!-- Github link -->
                <span class="link-block">
                  <a href="https://github.com/awjuliani/serotonin-ebm" target="_blank"
                    class="external-link button is-normal is-rounded is-dark">
                    <span class="icon">
                      <i class="fab fa-github"></i>
                    </span>
                    <span>Code</span>
                  </a>
                </span>

                <!-- ArXiv abstract Link -->
                <span class="link-block">
                  <a href="https://www.biorxiv.org/content/10.1101/2024.04.12.589282v2" target="_blank"
                    class="external-link button is-normal is-rounded is-dark">
                    <span class="icon">
                      <i class="ai ai-arxiv"></i>
                    </span>
                    <span>bioRxiv</span>
                  </a>
                </span>
                <!-- Youtube Link -->
                <span class="link-block">
                  <a href="https://www.youtube.com/watch?v=Mzlyc1AYGlo" target="_blank"
                    class="external-link button is-normal is-rounded is-dark">
                    <span class="icon">
                      <i class="fa-solid fa-video"></i>
                    </span>
                    <span>YouTube</span>
                  </a>
                </span>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Paper abstract -->
  <section class="section hero is-light">
    <div class="container is-max-desktop">
      <div class="columns is-centered has-text-centered">
        <div class="column is-four-fifths">
          <h2 class="title is-3">Abstract</h2>
          <div class="content has-text-justified">
            <p>
              Serotonergic psychedelics have been identified as promising next-generation therapeutic agents in the treatment of mood and anxiety disorders. While their efficacy has been increasingly validated, the mechanism by which they exert a therapeutic effect is still debated. A popular theoretical account is that excessive 5-HT2a agonism disrupts cortical dynamics, relaxing the precision of maladaptive high-level beliefs and making them more malleable and open to revision. We extend this perspective by developing a simple energy-based model of cortical dynamics based on predictive processing which incorporates effects of neuromodulation. Using this model, we propose and simulate hypothetical computational mechanisms for both 5-HT2a and 5-HT1a agonism. Results from our model are able to account for a number of existing empirical observations concerning serotonergic psychedelics effects on cognition and affect. Using the findings of our model, we provide a theoretically-grounded hypothesis for the clinical success of LSD, psilocybin, and DMT, as well as identify the design space of biased 5-HT1a agonist psychedelics such as 5-MeO-DMT as potentially fruitful in the development of more effective and tolerable psychotherapeutic agents in the future.
            </p>
          </div>
        </div>
      </div>
    </div>
  </section>
  <!-- End paper abstract -->

  <section class="hero is-small">
    <div class="hero-body">
      <div class="container  is-max-desktop">
        <h2 class="title is-3"></h2>
        <div class="level-set has-text-justified">
          <p>
            Classic psychedelics all have significant affinity for both the 5-HT2a and 5-HT1a receptors. Although 5-HT2a
            is responsible for the main psychedelic effects, 5-HT1a also plays a significant modulating role. We set out
            to computationally characterize both of these roles.
          </p>
          <br>
          <img src="static/images/fig1.png" alt="" class="blend-img-background center-image" />
        </div>
      </div>
    </div>
  </section>

  <section class="hero is-small">
    <div class="hero-body">
      <div class="container  is-max-desktop">
        <h2 class="title is-3"></h2>
        <div class="level-set has-text-justified">
          <p>
            We adopt the predictive processing framework and an energy-based model in which neural responses are the
            result of an optimization process on an energy landscape. During inference 'energy' is minimized, and during
            learning the 'predictive error' is minimized.
            Within this framework, many mental disorders (depression, OCD, etc) are understood as pathologies of
            optimization. Overly-precise and maladaptive priors manifest as local minima with steep gradients within the
            energy landscape, a phenomenon sometimes called canalization.
          </p>
          <br>
          <img src="static/images/fig2.png" alt="" class="blend-img-background center-image" />
        </div>
      </div>
    </div>
  </section>

  <section class="hero is-small">
    <div class="hero-body">
      <div class="container  is-max-desktop">
        <h2 class="title is-3"></h2>
        <div class="level-set has-text-justified">
          <p>
            We model 5-HT2a as injecting noise into the energy landscape, and 5-HT1a as smoothing it. The former results
            in acute overfitting during inference, while the latter in acute underfitting. Since many psychedelic (PSI,
            LSD, DMT) are mixed agonists, both happen simultaneously.
          </p>
          <br>
          <img src="static/images/fig3.png" alt="" class="blend-img-background center-image" />
        </div>
      </div>
    </div>
  </section>

  <!-- Subject Driven Video Generation carousel -->
  <section class="hero teaser">
    <div class="hero-body ">
      <div class="container is-max-desktop">
        <p>
          The overfitting of 5-HT2a is a special form of transient belief strengthening, one which has the typical
          neural signature of increased cortical entropy. The underfitting of 5-HT1a is a form of acute belief
          relaxation, and alone would only weakly increase cortical entropy.
        </p>

        <div id="results-carousel" class="carousel results-carousel">
          <div class="item item-video1 has-text-centered">
            <video poster="" id="header-video1" autoplay muted loop playsinline height="100%"
              src="static/videos/sim_1a_max_2a_max.mp4">
            </video>
            <h2 class="subtitle has-text-centered">
              Simulated effects of maximum levels of 5-HT2a and 5-HT1a agonism on energy landscape.</h2>
          </div>
          <div class="item item-video2 has-text-centered">
            <video poster="" id="header-video2" autoplay muted loop playsinline height="100%"
              src="static/videos/sim_1a_max_2a_zero.mp4">
            </video>
            <h2 class="subtitle has-text-centered">
              Simulated effects of maximum level of 5-HT1a agonism and zero 5-HT2a agonism on energy landscape.</h2>
          </div>
          <div class="item item-video3 has-text-centered">
            <video poster="" id="header-video3" autoplay muted loop playsinline height="100%"
              src="static/videos/sim_1a_zero_2a_max.mp4">
            </video>
            <h2 class="subtitle has-text-centered">
              Simulated effects of maximum level of 5-HT2a agonism and zero 5-HT1a agonism on energy landscape. </h2>
          </div>
          <div class="item item-video4 has-text-centered">
            <video poster="" id="header-video4" autoplay muted loop playsinline height="100%"
              src="static/videos/sim_1a_zero_2a_zero.mp4">
            </video>
            <h2 class="subtitle has-text-centered">
              Simulated effects of zero 5-HT2a and 5-HT1a agonism on energy landscape.</h2>
          </div>
        </div>
      </div>
    </div>
  </section>
  <!-- End Subject Driven Video Generation carousel -->


  <section class="hero is-small">
    <div class="hero-body">
      <div class="container  is-max-desktop">
        <h2 class="title is-3"></h2>
        <div class="level-set has-text-justified">
          <p>
            The results of our simulations suggest that 5-HT2a is responsible for long-term therapeutic effects, but at
            the cost of short-term acute tolerability. In contrast, 5-HT1a is acutely therapeutic and tolerable, but
            provides little long-term efficacy. Things get interesting when you mix both.
          </p>
          <br>
          <img src="static/images/fig4.png" alt="" class="blend-img-background center-image" />
        </div>
      </div>
    </div>
  </section>

  <section class="hero is-small">
    <div class="hero-body">
      <div class="container  is-max-desktop">
        <h2 class="title is-3"></h2>
        <div class="level-set has-text-justified">
          <p>
            In our model mixed agonists have greater long-term efficacy than 5-HT2a alone, while also being
            significantly more acutely tolerable. We find that if you want to optimize for both long-term and acute
            therapeutic effects an optimal agonism bias is towards 5-HT1a over 5-HT2a.
          </p>
          <br>
          <img src="static/images/fig5.png" alt="" class="blend-img-background center-image" />
          <br>
          <br>
          <p>
            5-MeO-DMT, a highly-biased 5-HT1a agonist, has received clinical attention for its potential to treat
            depression. Likewise for the co-administering of MDMA and LSD. There is a whole space of biased 5-HT1a
            agonists such as 5-MeO-MIPT which may also be worth exploring.
            Our work points to the importance of non-5HT2a receptor targets in the efficacy and tolerability of
            psychedelic therapy. Perhaps not surprisingly, the tryptamines have this profile, and the clinical success
            of psilocybin may be attributable to its unique mixed profile.

          </p>
        </div>
      </div>
    </div>
  </section>

  <section class="hero is-small">
    <div class="hero-body">
      <div class="container is-max-desktop has-text-centered">
        <h2 class="title is-3"><a href="./faq.html">Frequently Asked Questions</a></h2>
      </div>
    </div>
  </section>



  <!--BibTex citation -->
  <section class="section" id="BibTeX">
    <div class="container is-max-desktop content">
      <h2 class="title">BibTeX</h2>
      <pre><code>@article{juliani2024dual,
        title={A dual-receptor model of serotonergic psychedelics},
        author={Juliani, Arthur and Chelu, Veronica and Graesser, Laura and Safron, Adam},
        journal={bioRxiv},
        pages={2024--04},
        year={2024},
        publisher={Cold Spring Harbor Laboratory}
      }</code></pre>
    </div>
  </section>
  <!--End BibTex citation -->


  <footer class="footer">
    <div class="container">
      <div class="columns is-centered">
        <div class="column is-8">
          <div class="content">

            <p>
              This page was built using the <a href="https://github.com/eliahuhorwitz/Academic-project-page-template"
                target="_blank">Academic Project Page Template</a> which was adopted from theÂ <a
                href="https://nerfies.github.io" target="_blank">Nerfies</a>Â project page.
              You are free to borrow the of this website, we just ask that you link back to this page in the footer.
              <br> This website is licensed under a <a rel="license"
                href="http://creativecommons.org/licenses/by-sa/4.0/" target="_blank">Creative
                Commons Attribution-ShareAlike 4.0 International License</a>.
            </p>

          </div>
        </div>
      </div>
    </div>
  </footer>

  <!-- Statcounter tracking code -->

  <!-- You can add a tracker to track page visits by creating an account at statcounter.com -->

  <!-- End of Statcounter Code -->

</body>

</html>